文献速递关节外科创伤骨科

美国骨科委员会Part II考生报告的翻修髋膝关节置换VTE预防策略使用模式、疗效与并发症

Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Revision Hip and Knee Arthroplasty as Reported by American Board of Orthopaedic Surgery Part II Candidates.
PubMed 文献 · J Arthroplasty · 2021-02-02

本研究分析美国骨科委员会Part II口试病例数据库,纳入6387例翻修髋/膝关节置换术,比较激进与不激进静脉血栓栓塞症(VTE)预防策略的使用模式及并发症。结果显示不激进策略占35.3%,激进策略占64.7%;激进策略与更高的轻度/中度血栓、轻度/中度/重度出血、感染及90天内死亡风险相关,但不激进策略未增加血栓形成风险。

要点

  • 翻修髋/膝关节置换中不激进VTE预防策略占35.3%,激进策略占64.7%。
  • 激进策略与更高出血、血栓、感染及90天内死亡风险相关。
  • 不激进策略未显著增加血栓形成风险,致命性肺栓塞无差异。

核心结论

  • 激进VTE预防策略与更高的出血和血栓并发症率相关,而不激进策略未增加血栓形成风险。

研究设计与样本

  • 基于美国骨科委员会Part II口试病例列表数据库的回顾性分析,纳入6387例翻修髋/膝关节置换术。

主要发现

  • 不激进预防策略全国使用率为35.3%,激进策略为64.7%。
  • 不激进策略组无并发症患者比例为89.8%,激进策略组为81.9%(P < .001)。
  • 激进策略组轻度血栓事件1.2% vs 0.3%、轻度出血1.7% vs 0.6%、中度血栓2.6% vs 0.4%、中度出血6.2% vs 4.0%、重度出血4.4% vs 2.4%(均P < .001)。
  • 激进策略组感染6.4% vs 3.8%、90天内死亡3.1% vs 1.3%(均P < .001)。
  • 致命性肺栓塞发生率0.1% vs 0.04%(P = .474),无显著差异。

关键数值与推荐

  • 不激进预防策略定义为仅使用阿司匹林和/或序贯加压装置。
  • 激进预防策略定义为使用低分子肝素(依诺肝素)、华法林、利伐沙班、磺达肝癸钠或其他策略中的任何一种。

临床怎么用

  • 在翻修髋/膝关节置换术后选择VTE预防策略时,需权衡血栓与出血风险,不激进策略未增加血栓风险但需个体化评估。

局限性

  • 使用激进VTE预防策略的个体理由未知,研究为回顾性设计,证据等级为治疗性III级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimum venous thromboembolism (VTE) prophylaxis strategy to minimize risk of VTE and bleeding complications following revision total hip and knee arthroplasty (rTHA/rTKA) is controversial. The purpose of this study is to describe current VTE prophylaxis patterns following revision arthroplasty procedures to determine efficacy, complication rates, and prescribing patterns for different prophylactic strategies. METHODS: The American Board of Orthopaedic Surgery Part II (oral) examination case list database was analyzed. Current Procedural Terminology codes for rTHA/rTKA were queried and geographic region, VTE prophylaxis strategy, and complications were obtained. Less aggressive prophylaxis patterns were defined if only aspirin and/or sequential compression devises were utilized. More aggressive VTE prophylaxis patterns were considered if any of low-molecular-weight heparin (enoxaparin), warfarin, rivaroxaban, fondaparinux, or other strategies were used. RESULTS: In total, 6387 revision arthroplasties were included. The national rate of less aggressive VTE prophylaxis strategies was 35.3% and more aggressive in 64.7%. Use of less aggressive prophylaxis strategy was significantly associated with patients having no complications (89.8% vs 81.9%, P < .001). Use of more aggressive prophylaxis patterns was associated with higher likelihood of mild thrombotic (1.2% vs 0.3%, P < .001), mild bleeding (1.7% vs 0.6%, P < .001), moderate thrombotic (2.6% vs 0.4%, P < .001), moderate bleeding (6.2% vs 4.0%, P < .001), severe bleeding events (4.4% vs 2.4%, P < .001), infections (6.4% vs 3.8%, P < .001), and death within 90 days (3.1% vs 1.3%, P < .001). There were no significant differences in rates of fatal pulmonary embolism (0.1% vs 0.04%, P = .474). Subgroup analysis of rTHA and rTKA patients showed similar results. CONCLUSION: The individual rationale for using a more aggressive VTE prophylaxis strategy was unknown; however, more aggressive strategies were associated with higher rates of bleeding and thrombotic complications. Less aggressive strategies were not associated with a higher rate of thrombosis. LEVEL OF EVIDENCE: Therapeutic Level III.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Runner RP, Shau DN, Staley CA, et al. Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Revision Hip and Knee Arthroplasty as Reported by American Board of Orthopaedic Surgery Part II Candidates. J Arthroplasty. 2021. PMID: 33674164. doi:10.1016/j.arth.2021.01.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。